Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer

BACKGROUND: Small cell lung cancer (SCLC) is a recalcitrant malignancy with distinct biologic properties. Antibody targeting therapy has been actively investigated as a new drug modality. METHODS: We tested the expression of IGF-1R and calculated the survival in 61 SCLC patients. We also evaluated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Hongxin, Dong, Wei, Shen, Hongchang, Xu, Jun, Zhu, Linhai, Liu, Qi, Du, Jiajun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545894/
https://www.ncbi.nlm.nih.gov/pubmed/26287334
http://dx.doi.org/10.1371/journal.pone.0135844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545894/
https://www.ncbi.nlm.nih.gov/pubmed/26287334
http://dx.doi.org/10.1371/journal.pone.0135844

Ejemplares similares